IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma

• Status: Completed
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine which participants with melanoma have a better response to IL-2 and to identify markers that may predict response to IL-2 by collecting participant information (for example; cancer diagnosis and history, prior treatments for cancer, etc.) blood and tumor samples prior to treatment and tumor measurements after treatment.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dana-Farber Cancer Institute
• Treatments: Aldesleukin; Interleukin-2

Criteria

Inclusion Criteria:

• Malignant melanoma that is metastatic or unresectable

• Eligible to receive high-dose IL-2

• Tissue block available with adequate tumor to perform RNA extraction and DASL analysis

Exclusion Criteria:

• Prior immunotherapy for unresectable or metastatic disease

• Untreated brain metastases, leptomeningeal disease, or seizure disorder